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Summary
Introduction:  Providing  pain  relief  for  ankle  osteoarthritis  and  delaying  the  need  for  a  radical
surgery procedure  is  difﬁcult  to  achieve  with  analgesics  that  have  limited  efﬁcacy  or  are  not
devoid of  substantial  side  effects.
Hypothesis:  The  goals  of  this  study  were  to  evaluate  the  efﬁcacy  of  viscosupplementation,
explore which  factors  better  predict  Patient’s  response  and  propose  an  injection  protocol.
Materials  and  methods:  Eighteen  patients  (26  ankles)  with  ankle  osteoarthritis  were  included,
with seven  of  them  having  received  multiple  series  of  injections.  The  average  age  was  60  years.
Series of  three  injections,  performed  in  the  operating  room  under  ﬂuoroscopy-guidance,  were
evaluated  after  4  and  12  months  and  then  annually  with  the  AOFAS  score;  patient  satisfaction
was also  assessed.
Results:  The  average  AOFAS  score  increased  signiﬁcantly  from  61.8  ±  15  before  the  injections
to 74.4  ±  14.5  and  73.7  ±  16.6  after  4  and  12  months,  respectively.  The  average  follow-up  was
45.5 months  and  73%  of  patients  were  satisﬁed  or  very  satisﬁed.  There  were  no  adverse  effects
or intolerance.  In  patients  receiving  more  than  one  series  of  injections,  the  average  delay
between series  was  27.8  (range  15—43)  months.  Five  patients  had  a  radical  surgery  procedure
after an  average  of  27  months  of  effective  viscosupplementation.
Discussion:  This  prospective  study  showed  that  viscosupplementation  had  a  signiﬁcant  positive
effect (P  <  0.05)  in  patients  with  ankle  osteoarthritis  when  a  three-injection  protocol  was  used
every two  years  on  average.  Neither  etiology  nor  severity  of  the  osteoarthritis  was  predictive
of the  response.  In  our  opinion,  ﬂuoroscopy-guidance  is  essential  for  these  injections.
Level of  evidence:  Level  IV  coho
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ntroduction
lthough  osteoarthritis  (OA)  in  the  ankle  is  not  as  common
s  in  the  knee  or  hip,  it  can  be  very  painful  and  severely
ffect  walking  and  activities  of  daily  living  [1,2].  Conserva-
ive  management  of  arthritis  pain  must  delay  the  need  for
adical  surgery  procedures  such  as  fusion  or  joint  replace-
ent  and  limit  the  intake  of  NSAIDs.
Viscosupplementation,  which  consists  of  the  intra-
rticular  injection  of  hyaluronic  acid  (HA)  in  order  to  correct
uantitative  and  qualitative  changes  in  endogenous  HA  [3],
eems  to  relieve  the  symptoms  of  osteoarthritis.  Multiple
tudies  have  looked  at  the  efﬁcacy  of  viscosupplementa-
ion  for  knee  osteoarthritis  and  have  found  mostly  positive
esults  [4—8].
HA  has  a  visco-inductive  effect  in  vitro: the  addition  of
xogenous  HA  induces  the  synthesis  of  HA.  This  property  is
ore  apparent  with  high-molecular  weight  hyaluronic  acid
9].  It  contributes  to  its  regeneration  and  limits  interleukin-1
elated  inﬂammation  [10—14].  It  also  has  an  analgesic  effect
15—18]  and  a  chondroprotective  effect  [19—21]. The  HA
oncentration  is  2—3  mg/ml  in  normal  joints  and  is  reduced
o  0.8—2  mg/ml  in  joints  of  arthritic  patients  [22]. From  a
ualitative  point  of  view,  pathological  HA  molecules  are  0.5
nd  4.0  MDa  (millions  of  Dalton)  in  size,  versus  5.0  in  normal
ases  [23].  In  its  altered  state,  HA  contributes  to  inﬂam-
ation  [24]  and  no  longer  has  lubricating  and  hydrophilic
roperties.
Viscosupplementation  is  an  accepted  treatment  modality
or  knee  osteoarthritis.  But  only  a  few  clinical  trials  have
valuated  its  efﬁcacy  for  treating  ankle  osteoarthritis  up
o  now  [25—30].  This  study  had  three  objectives:  validate
 three-injection  treatment  protocol,  verify  the  efﬁcacy  of
A  in  the  ankle  and  look  for  factors  that  are  predictive  of
he  response.
aterials and methods
nclusion  and  exclusion  criteria
he  following  inclusion  criteria  were  used  for  the  prospec-
ive  series  carried  out  from  January  2003  to  December
009:  patients  presenting  with  Grade  1  or  2  talocrural
steoarthritis  based  on  the  Morrey  and  Wiedeman  classiﬁ-
ation  (Grade  0:  normal  ankle,  Grade  1:  small  osteophytes
nd  minimal  joint  narrowing,  Grade  2:  moderate  osteo-
hytes  and  moderate  joint  narrowing,  Grade  3:  signiﬁcant
arrowing  with  joint  deformation  or  fusion),  that  had
een  progressing  for  at  least  one  year  and  that  was
esistant  to  traditional  conservative  analgesic  treatment
31].
Although  concurrent  medications  were  not  recorded
uring  the  follow-up,  the  evaluation  score  took
nto  account  the  occasional  or  continuous  intake  of
nalgesics.
Exclusion  criteria  consisted  of  a  corticosteroid  injectionithin  the  last  month,  systemic  or  local  infection,  coagu-
ation  problems,  history  of  open  fracture,  known  allergy  to
yaluronic  acid  or  associated  conservative  surgery  proce-
ure  (arthroscopy,  calcaneal  osteotomy).
A
T
mFigure  1  Study  ﬂow  chart.
atients
hirty-three  patients  met  the  inclusion  criteria  and  49
njection  series  were  performed.  Patients  with  an  asso-
iated  surgery  were  excluded  to  obtain  a  case  series  of
atients  only  treated  by  viscosupplementation.  At  the  end,
8  patients  (26  ankles)  corresponded  to  our  criteria  and  were
he  subject  of  our  study  (Fig.  1).  The  series  consisted  of
ostly  men  (72%)  and  the  average  age  was  60  years  ±  14.7.
o  patients  were  lost  to  follow-up.  There  were  eight  right
nkles  for  every  ten  left  ankles.  Eleven  patients  received
nly  one  series  of  three  injections;  six  had  two  series;  one
ad  three  series.  Post-traumatic  osteoarthritis  was  the  most
ommon  etiology  (n  =  13),  including  chronic  laxity  (n  =  2)  and
steochondral  lesions  (n  =  2),  then  primary  arthritis  (n  =  5).
even  patients  had  Grade  1  OA  and  eleven  had  Grade  2  OA
ccording  to  the  Morrey  and  Wiedeman  classiﬁcation.
iscosupplementation  protocol
he  treatment  consisted  of  multiple  injections  from  an
mpule  of  high-molecular  weight  HA  (Synvisc® 6000  kD,  2  ml)
sing  a  standardized  technique.  The  protocol  always  com-
rised  three  injections,  15  days  apart;  this  was  considered
s  one  series.  The  injections  were  always  performed  on  an
utpatient  basis  in  the  operating  room  using  ﬂuoroscopy  sys-
em.  No  contrast  product  was  used.  The  ﬂuoroscopy  allowed
s  to  verify  the  needle  position  (Fig.  2).  After  mobilization
f  the  ankle,  full  weight-bearing  was  allowed  immediately,
hile  advising  the  patient  to  get  rest  during  the  following
ays.
A  new  series  of  three  injections  could  be  repeated  after
he  effect  had  worn  off  after  a  period  of  12  months.  Each
eries  was  considered  as  an  independent  parameter  from  a
tatistical  point  of  view.  In  cases  of  treatment  failure  or  no
esponse  to  treatment,  which  was  deﬁned  as  a  signiﬁcant
rop  in  the  AOFAS  score  (below  40/100),  a  radical  surgery
rocedure  was  proposed  to  the  patient.nalysis  methods
he  treatment  efﬁcacy  was  evaluated  at  4  months,  12
onths  and  then  every  year  thereafter  using  the  ankle
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variations  seen  depending  on  the  initial  AOFAS  grouping.  The
AOFAS  scores  are  summarized  in  Table  1.
Radical  surgical  treatment
Of  the  18  study  patients,  three  failures  were  noted  after
the  ﬁrst  series  and  two  after  the  second  series;  the  ini-
tial  positive  effect  lasted  for  24  months  on  average.  Ankle
joint  replacement  was  proposed  in  three  cases  and  tibio-
talocalcaneal  fusion  in  two  cases.  For  these  ﬁve  patients,
the  average  time  between  the  ﬁrst  injection  and  this  radical
surgery  was  27  months  (range  10—43)  (Table  2).
Discussion
We  used  a  treatment  protocol  currently  in  use  for  the  knee
joint  that  consisted  of  three  consecutive  injections,  15  days
apart.  Other  studies  have  used  different  methods  [28—30]  as
shown  in  Table  3. In  our  opinion,  use  of  this  three-injection
protocol  is  essential,  as  is  ﬂuoroscopy.  Our  study  conﬁrms
the  level  I  studies  showing  superiority  of  viscosupplementa-
tion  over  placebo  for  the  ankle  [26,28].
However,  a recent  level  I  study  with  high  theoreti-
cal  statistical  power  showed  little  difference  relative  to
placebo  [34].  But  this  study  used  a  non-recommended,
single-injection  protocol  with  low  molecular  weight  HA.
The  main  limitations  of  the  current  study  are  the  small
sample  size,  lack  of  a  control  group  and  lack  of  control  over
the  oral  analgesics  taken  by  the  patients.  Nevertheless,  the
inclusion  criteria  were  ankle  osteoarthritis  pain  that  had  not
been  alleviated  with  common  analgesics  for  at  least  one
year.
Table  2  Time  before  radical  surgery  and  AOFAS  score
before the  viscosupplementation  for  the  ﬁve  patients  who
failed  treatment.
AOFAS  score
before  injection
Time  before
surgical  treatment
(months)
73  42.8
41 27.0Figure  2  Fluoroscopy  used  to  verify  the  intra-articular  posi-
tion of  the  needle  before  the  injection.
functional  score  in  the  AOFAS  and  a  four-level  patient  sat-
isfaction  scale  (very  satisﬁed,  satisﬁed,  disappointed  or
dissatisﬁed).  The  evaluation  was  performed  by  an  indepen-
dent  evaluator.  All  adverse  effects  were  evaluated.  The
patients  were  grouped  by  severity  using  the  AOFAS  func-
tional  score  (stage  I  <  49/100;  stage  II  50  to  74/100;  stage
III  >  75/100).
The  change  in  the  AOFAS  score  was  analyzed  using  a
paired  Student’s  t-test.  Predictive  factors  were  explored
using  ANOVA  and  Mann-Whitney  Wilcoxon  tests,  with  a  sig-
niﬁcance  threshold  of  P  <  0.05.
Results
The  average  follow-up  was  45.5  months  (range  22.5—71.8),
with  no  patients  being  lost  to  follow-up.  No  adverse  effects
were  reported.
Subjective  effect  of  the  injections
Nineteen  of  the  26  injection  series  were  evaluated  was  being
satisfactory;  seven  were  considered  as  disappointing  with
three  leading  to  dissatisfaction.  The  average  time  elapsed
between  the  series  of  two  consecutive  injections  was  27.8
months  (range  15—43).Change  in  the  AOFAS  score
The  average  AOFAS  score  went  from  61.8  ±  15.0  before  the
viscosupplementation  to  73.7  ±  16.6  at  12  months  after,  with
61 10.4
46 12.6
49 42.4
Table  1  Change  in  the  overall  AOFAS  score  and  by  stage.
Before  4  months  12  months
AOFAS  overall  61.8  ±  15  74.4  ±  14.5  73.7  ±  16.6
AOFAS stage  I  (n  =  5)  40.2  (24—48)  56.2  (49—73)  60.8  (46—76)
AOFAS stage  II  (n  =  17)  63.2  (51—74)  76.0  (47—98)  73.6  (43—97)
AOFAS stage  III  (n  =  4)  83.2  (79—89)  90.2  (89—92)  90.2  (89—92)
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Table  3  Overview  of  studies  involving  viscosupplementation  treatment  for  ankle  arthritis  [32].
Study  Year  Level  Country  Average  age  Pts  Type  Fluoro  Outcome  Product  No.  Inj  Interval  Comparison  Average  FU
(months)
Effect
Lucas  y  Hernandez  et  al.  2013  IV  France  60  ±  14.7  26  Case  series  Yes  AOFAS  Synvisc® 3  15d  No  45.5  POS
Salk et  al.  [28]  2006  I  USA  58.8  ±  14.4  17  RCT  No  AOS  pain  Hyalgan® 5  7d  Saline  6  POS
Cohen et  al.  [26]  2008  I  USA  49.8  28  RCT  Yes  AOS  pain  Hyalgan® 5  7d  Saline  6  POS
Karatosun et  al.  [33]  2008  I  Turkey  55.1  30  RCT  No  AOFAS  Adant® 3  7d  PT  12  NEG
DeGroot et  al.  [34]  2012  I  USA  54.1  ±  14.5  56  RCT  Yes  AOFAS  Supartz® 1  N/A  Saline  3  NEG
Sun et  al.  [29]  2006  IV  Taiwan  50  ±  14.3  75  Case  series  No  AOFAS  Supartz® 5  7d  No  6  POS
Witteveen et  al.  [30]  2008  IV  Italy  41  ±  12.3  55  Case  series  No  AOS  pain  Synvisc® 1  or  2  ±3  mo  No  9  POS
Mei-Dan et  al.  [27]  2008  IV  Israel  35.5  ±  14.2  15  Case  series  No  AOFAS  Euﬂexxa® 3  7d  No  6  POS
Luciani et  al.  [35]  2008  IV  Italy  45  ±  15.9  21  Case  series  No  AOS  pain  Synvisc® 3  7d  No  18  POS
Inj: injections; RCT: randomized controlled trial; PT: physical therapy; FU: follow-up; Pts: number of patients; POS: HA had positive effect or was signiﬁcantly better; NEG: HA was not
signiﬁcantly better than control.
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Viscosupplementation  effect
The  current  study  showed  that  viscosupplementation  was
effective  against  pain.  Paradoxically,  this  effect  was  not  cor-
related  to  the  initial  condition  of  the  ankle.  The  pain  had
improved  in  73.1%  of  cases.  Nineteen  of  the  26  patients  were
satisﬁed  or  very  satisﬁed  with  the  treatment.  The  change
in  the  AOFAS  score  showed  that  the  treatment  efﬁcacy  was
extended  signiﬁcantly  during  the  entire  year  after  the  injec-
tion  series.  This  prolonged  effect  can  be  attributed  to  the
anti-inﬂammatory  action  of  hyaluronic  acid,  since  its  half-
life  in  the  joint  is  less  than  two  days.  This  positive  effect  can
be  extended:  15  of  the  26  cases  were  repeat  treatments.  Our
results  are  comparable  to  the  results  of  conservative  surgery
procedures  (arthroscopic  excision,  curetage,  microfracture,
chrondroplasty)  that  only  partially  and  temporarily  provide
pain  relief  [36,37].  This  work  substantiates  over  ten  years
of  clinical  experience  and  provides  objective  evidence  that
viscosupplementation  is  a  true  treatment  option  for  arthritic
ankles.
Duration  of  the  effect  and  predictive  factors
Our  study  conﬁrms  the  beneﬁt  for  patients  of  this  temporary
analgesic  treatment.  The  goal  of  using  alternative  treat-
ments  is  to  completely  avoid  if  possible,  or  at  least  delay,
the  need  for  radical  treatment.  Viscosupplementation  can
be  proposed  no  matter  the  etiology.  However,  the  indica-
tion  should  only  be  made  in  patients  with  sufﬁcient  joint
mobility  (overall  range  of  motion  >  40◦)  and  without  large
osteophytes  that  could  hinder  joint  space  clearance  or  make
the  injections  difﬁcult  to  perform,  even  with  ﬂuoroscopy.
In  our  series,  the  treatment  efﬁcacy  extended  to  an  aver-
age  of  27.8  months,  which  is  greater  than  the  accepted
protocol  for  the  knee  (repeated  yearly).  Our  study  found
no  signiﬁcant  relationship  between  the  AOFAS  score  and  the
etiology  of  the  OA  or  the  progression  of  the  OA.  We  did
not  ﬁnd  any  factors  that  predicted  a  good  response  to  this
treatment.  These  factors  are  poorly  deﬁned  [33,38,39].  As
of  now,  there  is  no  evidence  to  suggest  that  the  treatment
response  is  better  as  a  function  of  the  molecular  weight  of
the  hyaluronic  acid  for  knee  osteoarthritis  pain,  and  as  an
extension,  for  the  ankle  [40—44].
In  our  opinion,  one  of  the  basic  requirements  is  that
injections  be  performed  under  ﬂuoroscopy,  to  be  sure  the
HA  is  being  injected  into  the  joint  space.  Only  two  studies
have  used  this  protocol  [26,34].  We  believe  this  procedure
avoids  the  injection  site  complications  found  in  other  stud-
ies  (inﬂammation  and  pain  at  the  injection  site)  and  ensures
that  good  results  will  be  achieved,  as  pointed  out  in  many
reviews  on  this  topic  [30,45,46].
Published  reviews  have  shown  the  superiority  of  multiple
HA  injections  versus  placebo  in  Level  I  studies  (pain,  AOFAS
score)  and  a  positive  effect  in  level  IV  studies  (pain,  AOFAS
score),  but  not  difference  between  HA  and  corticosteroid
injections  [46—48].Conclusion
Our  study  conﬁrms  the  efﬁcacy  of  viscosupplementation
using  a  protocol  of  three  consecutive  injections,  15  days
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part  for  all  patients  with  ankle  osteoarthritis,  no  matter  the
tiology,  having  Grade  1  or  Grade  2  disease  according  to  the
orrey  and  Wiedeman  classiﬁcation.  This  effect  was  appar-
nt  at  four  months  and  was  maintained  out  to  12  months;
t  became  less  marked  after  about  28  months  on  average.
lso,  since  a  certain  number  of  patients  eventually  fail  with
his  treatment,  our  study  showed  that  this  option  delayed
adical  surgery  by  an  average  of  27  months.
The  strong  points  of  this  study  are  the  long  follow-up,  and
hat  each  patient  had  the  option,  if  desired,  to  receive  a  new
eries  of  three  injections  if  the  ﬁrst  series  was  effective  and
he  effect  had  faded  (AOFAS  score  dropping  below  the  initial
OFAS  score).
When  performed  within  certain  prescribed  limits  (aseptic
urgery  conditions,  ﬂuoroscopy-guidance,  three-injection
rotocol,  use  of  high-molecular  weight  HA),  viscosupple-
entation  provides  clear-cut  and  long-lasting  pain  relief
hat  can  be  repeated  as  many  times  as  necessary  until  a
ore  radical  surgery  procedure  is  needed.
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